The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
M | Musculo-skeletal system | |
2
|
M01 | Antiinflammatory and antirheumatic products | |
3
|
M01A | Antiinflammatory and antirheumatic products, non-steroids | |
4
|
M01AC | Oxicams |
| Code | Title | |
|---|---|---|
| M01AC01 | Piroxicam | |
| M01AC02 | Tenoxicam | |
| M01AC04 | Droxicam | |
| M01AC05 | Lornoxicam | |
| M01AC06 | Meloxicam | |
| M01AC56 | Meloxicam, combinations |
| Active Ingredient |
|---|
|
|
|
Lornoxicam is a non-steroidal anti-inflammatory drug with analgesic properties and belongs to the class of oxicams. Lornoxicams mode of action is mainly related to the inhibition of the prostaglandin synthesis (inhibition of the cyclooxygenase enzyme) leading to desensitisation of peripheral nociceptors and consequently inhibition of inflammation. A central effect on nociception, which seems to be independent of anti-inflammatory effects has also been suggested. |
|
Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam family, with anti-inflammatory, analgesic and antipyretic properties. The anti-inflammatory activity of meloxicam has been proven in classical models of inflammation. As with other NSAID, its precise mechanism of action remains unknown. However, there is at least one common mode of action shared by all NSAID (including meloxicam): inhibition of the biosynthesis of prostaglandins, known inflammation mediators. |
|
Piroxicam is a non-steroidal anti-inflammatory agent with analgesic and antipyretic activity. It is effective regardless of the aetiology of the inflammation. |
|
Tenoxicam is a non-steroidal anti-inflammatory drug (NSAID) which has anti-inflammatory, analgesic, antipyretic properties and it also inhibits platelet aggregation. |
| Document | Type | Information Source | |
|---|---|---|---|
| FELDENE Capsule, FELDENE D Tablet | MPI, EU: SmPC | Pharmaceutical Benefits Scheme (AU) | |
| FLAMARYX Tablet | MPI, Generic | Health Products Regulatory Authority (ZA) | |
| MELCAM Tablet | MPI, EU: SmPC | Health Products Regulatory Authority (IE) | |
| MELOREX Tablet | MPI, EU: SmPC | Medicines and Medical Devices Safety Authority (NZ) | |
| MELOX Tablet | MPI, EU: SmPC | Υπουργείο Υγείας (CY) | |
| MOBIC Tablet | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
| MOBIFLEX Film-coated tablet | MPI, EU: SmPC | Medicines & Healthcare Products Regulatory Agency (GB) | |
| MOXICAM Tablet | MPI, EU: SmPC | ||
| PIXICAM Dispersible tablet | MPI, Generic | Health Products Regulatory Authority (ZA) | |
| PYROCAPS Capsule | MPI, Generic | Health Products Regulatory Authority (ZA) | |
| SOTILEN Capsule | MPI, EU: SmPC | Υπουργείο Υγείας (CY) | |
| XEFO Film-coated tablets | MPI, EU: SmPC | Health Products Regulatory Authority (IE) | |
| XEFO Powder and solvent for solution for injection | MPI, EU: SmPC |